Company Overview and News

 
Nestle, Unilever, Coke make bids in US$4b-plus GSK India sale — sources

2018-09-19 theedgemarkets
LONDON (Sept 19): Nestle, Unilever and Coca-Cola are among bidders for GlaxoSmithKline's Indian Horlicks nutrition business, expected to fetch more than US$4 billion, four people familiar with the matter said.
GSKCONS 500676

 
Nestle, Unilever, Coke make bids in US$4 billion-plus GSK India sale: Sources

2018-09-18 channelnewsasia
Nestle , Unilever and Coca-Cola are among bidders for GlaxoSmithKline's Indian Horlicks nutrition business, expected to fetch more than US$4 billion, four people familiar with the matter said.
GSKCONS 500676

 
Exclusive: Nestle, Unilever, Coke make bids in US$4 billion-plus GSK India sale - sources

2018-09-18 channelnewsasia
Nestle , Unilever and Coca-Cola are among bidders for GlaxoSmithKline's Indian Horlicks nutrition business, expected to fetch more than US$4 billion, four people familiar with the matter said.
GSKCONS 500676

 
Nestle, Unilever, Coke make bids in $4 billion-plus GSK India sale

2018-09-18 moneycontrol
Nestle, Unilever and Coca-Cola are among bidders for GlaxoSmithKline's Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said.
GSKCONS 500676

 
Nestle, Unilever, Coke make bids in $4 billion-plus GSK India sale: report

2018-09-18 livemint
London: Nestle, Unilever and Coca-Cola are among bidders for GlaxoSmithKline’s Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said.
GSKCONS 500676

 
Exclusive: Nestle, Unilever, Coke make bids in $4 billion-plus GSK India sale - sources

2018-09-18 reuters
LONDON (Reuters) - Nestle (NESN.S), Unilever (ULVR.L) (UNc.AS) and Coca-Cola (KO.N) are among bidders for GlaxoSmithKline’s (GSK.L) Indian Horlicks nutrition business, expected to fetch more than $4 billion, four people familiar with the matter said.
GSKCONS 500676

 
GlaxoSmithKline Consumer Healthcare Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-09-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GSKCONS 500676

 
GSK sets mid-Sept deadline for sale of India consumer biz, seeks over $4bn: report

2018-08-23 moneycontrol
British pharmaceutical giant GlaxoSmithKline (GSK) has called for bids for its Indian consumer nutrition business by mid-September. The business includes popular malted milk drink Horlicks; malt-based drink Boost; Viva, a beverage that contains wheat and barley; and chocolate caramel drink Maltova. Bloomberg reports the proposed deal is estimated to be around $4.5 billion.
532321 GSKCONS 500696 KO HINDUNILVR 500676 CDLYY CADILAHC

6
Glaxo heads for record in India ahead of consumer business sale

2018-08-23 theedgemarkets
MUMBAI (Aug 23): GlaxoSmithKline Consumer Healthcare Ltd is headed for a record high after parent GlaxoSmithKline Plc was said to have requested bids by mid-September for its Indian consumer-health unit.
PEP GSKCONS NVS GSK 500676 RB GSK

4
GSK seeks mid-Sept bids for Horlicks India unit

2018-08-22 freepressjournal.in
Mumbai : GlaxoSmithKline is seeking initial bids by mid-September for its India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, according to sources.
GSKCONS GSK 500676 GSK

6
GlaxoSmithKline said to seek bids mid-September for $4 billion India sale

2018-08-22 livemint
Mumbai: UK pharmaceutical giant GlaxoSmithKline Plc has requested bids by mid-September for its $4.3 billion Indian consumer-health unit, which owns the popular malted milk brand Horlicks, people with knowledge of the matter said. Glaxo has sent out an information memorandum with preliminary details about the business to possible suitors, according to the people, who asked not to be identified because the information is private.
PEP GSKCONS NVS GSK 500676 RB GSK

6
Glaxo said to seek bids mid-Sept for US$4 bil India sale

2018-08-21 theedgemarkets
MUMBAI/LONDON (Aug 21): U.K. pharmaceutical giant GlaxoSmithKline Plc has requested bids by mid-September for its US$4.3 billion Indian consumer-health unit, which owns the popular malted milk brand Horlicks, people with knowledge of the matter said.
PEP GSKCONS NVS GSK 500676 RB GSK

 
GSK seeks mid-Sept bids for $4 bln Indian Horlicks unit -sources

2018-08-21 reuters
LONDON (Reuters) - GlaxoSmithKline (GSK.L) is seeking initial bids by mid-September for its India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, two people familiar with the situation said on Tuesday.
GSKCONS 500676

 
GlaxoSmithKline Consumer Healthcare Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-08-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GSKCONS 500676

 
GlaxoSmithKline Consumer Healthcare Limited - Shareholders meeting

2018-08-08 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GSKCONS 500676

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...